(Q33566124)

28 July 2017

1 reference

title

The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements (English)

1 reference

28 July 2017

0 references

1

Robert W Buchanan

1 reference

28 July 2017

Julie Kreyenbuhl

2

1 reference

28 July 2017

Deanna L Kelly

3

1 reference

28 July 2017

Jason M Noel

4

1 reference

28 July 2017

Douglas L Boggs

5

1 reference

28 July 2017

Bernard A Fischer

6

1 reference

28 July 2017

Seth Himelhoch

7

1 reference

28 July 2017

Beverly Fang

8

1 reference

28 July 2017

Eunice Peterson

9

1 reference

28 July 2017

Patrick R Aquino

10

1 reference

28 July 2017

William Keller

11

1 reference

28 July 2017

Schizophrenia Patient Outcomes Research Team (PORT)

12

1 reference

28 July 2017

language of work or name

English

0 references

publication date

2 December 2009

1 reference

28 July 2017

published in

Schizophrenia Bulletin

1 reference

28 July 2017

volume

36

1 reference

28 July 2017

issue

1

1 reference

28 July 2017

page(s)

71-93

1 reference

The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements

28 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

A meta-analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Extrapyramidal side-effects of antipsychotics in a randomised trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Adverse effects of atypical antipsychotics : differential risk and clinical implications

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

The metabolic effects of antipsychotic medications

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Olanzapine and haloperidol in first episode psychosis: two-year data

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Aripiprazole for schizophrenia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic

21 June 2018

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

21 June 2018

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment

21 January 2018

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

21 June 2018

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Influence of atypical neuroleptics on executive functioning in patients with schizophrenia: a randomized, double-blind comparison of olanzapine vs. clozapine

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Antipsychotic drugs and QT prolongation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Pharmacological management of acute agitation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

First-episode schizophrenia: a focus on pharmacological treatment and safety considerations

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Suicidal risk during treatment with clozapine: a meta-analysis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Two-year follow-up of a smoking cessation trial in patients with schizophrenia: increased rates of smoking cessation and reduction

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Practice guideline for the treatment of patients with schizophrenia, second edition.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

The rate, pattern, and cost of use of antiparkinsonian agents among patients treated for schizophrenia in a managed care setting.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Psychopharmacology: Underuse of Evidence-Based Treatments in Psychiatry

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Investigation of the potential of clozapine to cause torsade de pointes

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Determining the optimal dose of haloperidol in first-episode psychosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Electrocardiographic abnormalities in patients treated with clozapine

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Patterns of usual care for schizophrenia: initial results from the Schizophrenia Patient Outcomes Research Team (PORT) Client Survey

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Conventional antipsychotic medications for schizophrenia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Emerging uses for high-potency benzodiazepines in psychotic disorders

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Rapid tranquillisation. A survey of emergency prescribing in a general psychiatric hospital

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Discovering the neural basis of human social anxiety: a diagnostic and therapeutic imperative

21 June 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

Arterial stiffness and stroke in hypertension: therapeutic implications for stroke prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

Association of autonomic dysfunction and clozapine. Heart rate variability and risk for sudden death in patients with schizophrenia on long-term psychotropic medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

A Double-Blind, Randomized, Placebo-Controlled Trial of Olanzapine in the Prevention of Psychotic Relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

Olanzapine treatment of residual positive and negative symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

Mortality in current and former users of clozapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia: population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

Oral risperidone plus oral lorazepam versus standard care with intramuscular conventional neuroleptics in the initial phase of treating individuals with acute psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

A placebo controlled trial of bupropion for smoking cessation in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

A double-blind placebo-controlled cross over trial of bupropion in smoking reduction in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

Transcranial magnetic stimulation for auditory hallucinations in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

Transcranial magnetic stimulation in the treatment of schizophrenic symptoms: a double blind sham controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

Slow transcranial magnetic stimulation can rapidly reduce resistant auditory hallucinations in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

Is rTMS efficient as a maintenance treatment for auditory verbal hallucinations? A case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

Second run of transcranial magnetic stimulation has no effects on persistent auditory hallucinations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

Effects of repetitive transcranial magnetic stimulation on auditory hallucinations refractory to clozapine.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

A randomized controlled trial of a smoking cessation intervention among people with a psychotic disorder.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Asian outpatients with schizophrenia: a double-blind randomized comparison of quality of life and clinical outcomes for patients treated with olanzapine or haloperidol.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Clozapine diminishes suicidal behavior: a retrospective evaluation of clinical records.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

The Efficacy of High-Dose Olanzapine Versus Clozapine in Treatment-Resistant Schizophrenia: A Double-Blind Crossover Study

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Atypical and Conventional Antipsychotic Drugs in Treatment-Naive First-Episode Schizophrenia: A 52-Week Randomized Trial of Clozapine Vs Chlorpromazine

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Impact of clozapine on completed suicide

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

A Randomized Controlled Trial of a Smoking Cessation Intervention Among People With a Psychotic Disorder

31 October 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBP116

Should we treat auditory hallucinations with repetitive transcranial magnetic stimulation? A metaanalysis

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2800144

QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients

31 October 2018

1 reference

12 December 2020

Clozapine for Treatment-Refractory Schizophrenia, Schizoaffective Disorder, and Psychotic Bipolar Disorder

1 reference

12 December 2020

Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia

1 reference

12 December 2020

First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies

1 reference

12 December 2020

The Texas Medication Algorithm Project Antipsychotic Algorithm for Schizophrenia

1 reference

12 December 2020

Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study

1 reference

12 December 2020

Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting

1 reference

12 December 2020

Electrocardiogram and cardiovascular changes in thioridazine and chlorpromazine poisoning

1 reference

12 December 2020

Benzodiazepines combined with neuroleptics for management of severe disruptive behavior

1 reference

12 December 2020

Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking

1 reference

12 December 2020

Repetitive transcranial magnetic stimulation in schizophrenic patients reporting auditory hallucinations

1 reference

12 December 2020

The treatment of recurring auditory hallucinations in schizophrenia with rTMS

1 reference

12 December 2020

The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia

1 reference

12 December 2020

Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes

1 reference

12 December 2020

Efficacy of slow repetitive transcranial magnetic stimulation in the treatment of resistant auditory hallucinations in schizophrenia: a meta-analysis

1 reference

12 December 2020

Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study

1 reference

12 December 2020

A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia

1 reference

12 December 2020

Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison

1 reference

12 December 2020

Successful use of maintenance rTMS for 8 months in a patient with antipsychotic-refractory auditory hallucinations

1 reference

12 December 2020

Maintenance Treatment With Transcranial Magnetic Stimulation in a Patient With Late-Onset Schizophrenia

1 reference

12 December 2020

Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges

1 reference

12 December 2020

Identifiers

DOI

10.1093/SCHBUL/SBP116

1 reference

28 July 2017

1 reference

28 July 2017

1 reference